John Goldman

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Goldman J M; Green A R; Holyoake T; Jamieson C; Mesa R; Mughal T; Pellicano F; Perrotti D; Skoda R; Vannucchi A M
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.
Marin David; Khorashad Jamshid S; Foroni Letizia; Milojkovic Dragana; Szydlo Richard; Reid Alistair G; Rezvani Katayoun; Bua Marco; Goldman John M; Apperley Jane F
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
Yong Agnes S M; Keyvanfar Keyvan; Hensel Nancy; Eniafe Rhoda; Savani Bipin N; Berg Maria; Lundqvist Andreas; Adams Sharon; Sloand Elaine M; Goldman John M; Childs Richard; Barrett A John
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of John Goldman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Goldman J M; Green A R; Holyoake T; Jamieson C; Mesa R; Mughal T; Pellicano F; Perrotti D; Skoda R; Vannucchi A M
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(10):1708-15.
2009: Marin David; Khorashad Jamshid S; Foroni Letizia; Milojkovic Dragana; Szydlo Richard; Reid Alistair G; Rezvani Katayoun; Bua Marco; Goldman John M; Apperley Jane F
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
British journal of haematology 2009;145(3):373-5.
2009: Yong Agnes S M; Keyvanfar Keyvan; Hensel Nancy; Eniafe Rhoda; Savani Bipin N; Berg Maria; Lundqvist Andreas; Adams Sharon; Sloand Elaine M; Goldman John M; Childs Richard; Barrett A John
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
Blood 2009;113(4):875-82.
2008: Marin David; Milojkovic Dragana; Olavarria Eduardo; Khorashad Jamshid S; de Lavallade Hugues; Reid Alistair G; Foroni Letizia; Rezvani Katayoun; Bua Marco; Dazzi Francesco; Pavlu Jiri; Klammer Matthias; Kaeda Jaspal S; Goldman John M; Apperley Jane F
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Blood 2008;112(12):4437-44.
2008: Khorashad Jamshid S; de Lavallade Hugues; Apperley Jane F; Milojkovic Dragana; Reid Alistair G; Bua Marco; Szydlo Richard; Olavarria Eduardo; Kaeda Jaspal; Goldman John M; Marin David
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4806-13.
2008: Mohty Mohamad; Szydlo Richard M; Yong Agnes S M; Apperley Jane F; Goldman John M; Melo Junia V
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.
Blood 2008;112(5):2163-6.
2008: Yong A S M; Keyvanfar K; Eniafe R; Savani B N; Rezvani K; Sloand E M; Goldman J M; Barrett A J
Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(9):1721-7.
2008: Khorashad J S; Thelwell N; Milojkovic D; Marin D; Watson J A; Goldman J M; Apperley J F; Foroni L; Reid A G
A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
Journal of clinical pathology 2008;61(7):863-5.
2008: de Lavallade Hugues; Apperley Jane F; Khorashad Jamshid S; Milojkovic Dragana; Reid Alistair G; Bua Marco; Szydlo Richard; Olavarria Eduardo; Kaeda Jaspal; Goldman John M; Marin David
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3358-63.
2008: de Lavallade Hugues; Punnialingam Sinthiya; Milojkovic Dragana; Bua Marco; Khorashad Jamshid S; Gabriel Ian H; Chaidos Aristeidis; Olavarria Eduardo; Goldman John M; Apperley Jane F; Marin David
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
British journal of haematology 2008;141(5):745-7.
2008: Khorashad Jamshid S; Milojkovic Dragana; Mehta Puja; Anand Mona; Ghorashian Sara; Reid Alistair G; De Melo Valeria; Babb Anna; de Lavallade Hugues; Olavarria Eduardo; Marin David; Goldman John M; Apperley Jane F; Kaeda Jaspal S
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Blood 2008;111(4):2378-81.
2008: Goldman John M; Melo Junia V
BCR-ABL in chronic myelogenous leukemia--how does it work?
Acta haematologica 2008;119(4):212-7.
2007: Olavarria Eduardo; Siddique Shamyla; Griffiths Michael J; Avery Sharon; Byrne Jenny L; Piper Karen P; Lennard Anne L; Pallan Lalit; Arrazi Julie M; Perz Jolanta B; O'Shea Derville; Goldman John M; Apperley Jane F; Craddock Charles F
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
Blood 2007;110(13):4614-7.
2007: De Melo Valeria A S; Milojkovic Dragana; Khorashad Jamshid S; Marin David; Goldman John M; Apperley Jane F; Reid Alistair G
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
Blood 2007;110(8):3086-7.
2007: de Lavallade Hugues; Khorashad Jamshid S; Davis Howard P; Milojkovic Dragana; Kaeda Jaspal S; Goldman John M; Apperley Jane F; Marin David
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.
Blood 2007;110(7):2779-80.
2007: Goldman John M
How I treat chronic myeloid leukemia in the imatinib era.
Blood 2007;110(8):2828-37.
2007: Yong Agnes S M; Rezvani Katayoun; Savani Bipin N; Eniafe Rhoda; Mielke Stephan; Goldman John M; Barrett A John
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.
Blood 2007;110(2):770-5.
2007: Pavlu Jiri; Andreasson Catharina; Chuah Charles; Kaeda Jaspal; Goldman John M; Apperley Jane F; Marin David
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
British journal of haematology 2007;137(5):423-8.
2007: Simula M P; Marktel S; Fozza C; Kaeda J; Szydlo R M; Nadal E; Bua M; Rahemtulla A; Kanfer E; Marin D; Olavarria E; Goldman J M; Apperley J F; Dazzi F
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(5):943-8.
2007: Mughal Tariq; Goldman John M
Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.
Clinical lymphoma & myeloma 2007;7 Suppl 3():S95-101.
2007: Mughal Tariq I; Goldman John M
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
Clinical lymphoma & myeloma 2007;7 Suppl 2():S81-4.
2007: Fozza C; Szydlo R M; Abdel-Rehim M M; Nadal E; Goldman J M; Apperley J F; Dazzi F
Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose.
British journal of haematology 2007;136(6):833-6.
2007: David Marianna; Cross Nicholas C P; Burgstaller Sonja; Chase Andrew; Curtis Claire; Dang Raymond; Gardembas Martine; Goldman John M; Grand Francis; Hughes George; Huguet Francoise; Lavender Louise; McArthur Grant A; Mahon Francois X; Massimini Giorgio; Melo Junia; Rousselot Philippe; Russell-Jones Robin J; Seymour John F; Smith Graeme; Stark Alastair; Waghorn Katherine; Nikolova Zariana; Apperley Jane F
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
Blood 2007;109(1):61-4.
2006: Mughal Tariq I; Goldman John M
Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia.
Clinical medicine (London, England) 2006;6(6):526-8.
2006: Anand Mona; Khorashad Jamshid; Marin David; Apperley Jane F; Goldman John M; Kaeda Jaspal Singh
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.
Blood 2006;108(8):2881-2.
2006: Kaeda Jaspal; O'Shea Derville; Szydlo Richard M; Olavarria Eduardo; Dazzi Francesco; Marin David; Saunders Susan; Khorashad Jamshid S; Cross Nicholas C P; Goldman John M; Apperley Jane F
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.
Blood 2006;107(10):4171-6.
2006: Khorashad J S; Anand M; Marin D; Saunders S; Al-Jabary T; Iqbal A; Margerison S; Melo J V; Goldman J M; Apperley J F; Kaeda J
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(4):658-63.
2006: Yong Agnes S M; Szydlo Richard M; Goldman John M; Apperley Jane F; Melo Junia V
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.
Blood 2006;107(1):205-12.
2006: Mughal Tariq I; Goldman John M
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Frontiers in bioscience : a journal and virtual library 2006;11():209-20.
2006: Mughal Tariq I; Goldman John M
Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?
Frontiers in bioscience : a journal and virtual library 2006;11():198-208.
2005: Barnes David J; Palaiologou Danai; Panousopoulou Eleni; Schultheis Beate; Yong Agnes S M; Wong Alice; Pattacini Laura; Goldman John M; Melo Junia V
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Cancer research 2005;65(19):8912-9.
2005: Marin David; Kaeda Jaspal S; Andreasson Catharina; Saunders Sue M; Bua Marco; Olavarria Eduardo; Goldman John M; Apperley Jane F
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Cancer 2005;103(9):1850-5.
2005: Goldman John M
A unifying mutation in chronic myeloproliferative disorders.
The New England journal of medicine 2005;352(17):1744-6.
2005: Marin D; Kaeda J; Szydlo R; Saunders S; Fleming A; Howard J; Andreasson C; Bua M; Olavarria E; Rahemtulla A; Dazzi F; Kanfer E; Goldman J M; Apperley J F
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(4):507-12.
2004: Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman J M; Apperley J F; Rahemtulla A
Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(8):1420-6.
2004: Tipping A J; Baluch S; Barnes D J; Veach D R; Clarkson B M; Bornmann W G; Mahon F X; Goldman J M; Melo J V
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(8):1352-6.
2004: Mughal Tariq I; Goldman John M
Chronic myeloid leukemia: current status and controversies.
Oncology (Williston Park, N.Y.) 2004;18(7):837-44, 847; discussion 847-50, 853-4.
2004: Avery S; Nadal E; Marin D; Olavarria E; Kaeda J; Vulliamy T; Brito Babapulle F; Goldman J M; Apperley J F
Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
Leukemia research 2004;28 Suppl 1():S75-7.
2004: Goldman John M
Chronic myeloid leukemia-still a few questions.
Experimental hematology 2004;32(1):2-10.
2004: Jordan William J; Brookes Paul A; Szydlo Richard M; Goldman John M; Lechler Robert I; Ritter Mary A
IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation.
Blood 2004;103(2):717-24.
2003: Tipping Alex J; Deininger Michael W; Goldman John M; Melo Junia V
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Experimental hematology 2003;31(11):1073-80.
2003: Goldman John M
Myeloproliferative and myelodysplastic syndromes: the future.
Hematology/oncology clinics of North America 2003;17(5):1261-9.
2003: Goldman John M; Melo Junia V
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
The New England journal of medicine 2003;349(15):1451-64.
2003: Terpos Evangelos; Politou Marianna; Szydlo Richard; Goldman John M; Apperley Jane F; Rahemtulla Amin
Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.
British journal of haematology 2003;123(1):106-9.
2003: Terpos Evangelos; de la Fuente Josu; Szydlo Richard; Hatjiharissi Evdoxia; Viniou Nora; Meletis John; Yataganas Xenophon; Goldman John M; Rahemtulla Amin
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
International journal of cancer. Journal international du cancer 2003;106(3):455-7.
2003: Marin David; Marktel Sarah; Szydlo Richard; Klein John P; Bua Marco; Foot Nicola; Olavarria Eduardo; Shepherd Pat; Kanfer Edward; Goldman John M; Apperley Jane F
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
Lancet 2003;362(9384):617-9.
2003: Marin D; Marktel S; Bua M; Szydlo R M; Franceschino A; Nathan I; Foot N; Crawley C; Na Nakorn T; Olavarria E; Lennard A; Neylon A; O'Brien S G; Goldman J M; Apperley J F
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(8):1448-53.
2003: Gordon Myrtle Y; Marley Stephen B; Apperley Jane F; Marin David; Kaeda Jaspal; Szydlo Richard; Goldman John M
Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons.
British journal of haematology 2003;122(3):424-9.
2003: Terpos Evangelos; Szydlo Richard; Apperley Jane F; Hatjiharissi Evdoxia; Politou Marianna; Meletis John; Viniou Nora; Yataganas Xenophon; Goldman John M; Rahemtulla Amin
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.
Blood 2003;102(3):1064-9.
2003: Dong Rong; Cwynarski Kate; Entwistle Alan; Marelli-Berg Federica; Dazzi Francesco; Simpson Elizabeth; Goldman John M; Melo Junia V; Lechler Robert I; Bellantuono Ilaria; Ridley Anne; Lombardi Giovanna
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.
Blood 2003;101(9):3560-7.
2003: Goldman John M; Marin David; Olavarria Eduardo; Apperley Jane F
Clinical decisions for chronic myeloid leukemia in the imatinib era.
Seminars in hematology 2003;40(2 Suppl 2):98-103; discussion 104-13.
2003: Marktel Sarah; Marin David; Foot Nicola; Szydlo Richard; Bua Marco; Karadimitris Anastasios; De Melo Valeria A S; Kotzampaltiris Paul; Dazzi Francesco; Rahemtulla Amin; Olavarria Eduardo; Apperley Jane F; Goldman John M
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
Haematologica 2003;88(3):260-7.
2003: Mahon François-Xavier; Belloc Francis; Lagarde Valérie; Chollet Claudine; Moreau-Gaudry François; Reiffers Josy; Goldman John M; Melo Junia V
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
Blood 2003;101(6):2368-73.
2003: Terpos E; Apperley J F; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman J M; Rahemtulla A
Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Bone marrow transplantation 2003;31(3):163-70.
2003: Marin David; Marktel Sarah; Foot Nicola; Bua Marco; Goldman John M; Apperley Jane F
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
Haematologica 2003;88(2):227-9.
2003: Amrolia Persis J; Reid Steven D; Gao Liquan; Schultheis Beate; Dotti Gianpietro; Brenner Malcolm K; Melo Junia V; Goldman John M; Stauss Hans J
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
Blood 2003;101(3):1007-14.
2003: Terpos Evangelos; Viniou Nora; de la Fuente Josu; Meletis John; Voskaridou Ersi; Karkantaris Christos; Vaiopoulos George; Palermos John; Yataganas Xenophon; Goldman John M; Rahemtulla Amin
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
European journal of haematology 2003;70(1):34-42.
2003: Goldman John M; Marin David
Management decisions in chronic myeloid leukemia.
Seminars in hematology 2003;40(1):97-103.
2002: Alenzi Faris Q B; Marley Stephen B; Lewis John L; Chandrashekran Anil; Warrens Anthony N; Goldman John M; Gordon Myrtle Y
A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics.
Experimental hematology 2002;30(12):1428-35.
2002: Tipping A J; Mahon F X; Zafirides G; Lagarde V; Goldman J M; Melo J V
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(12):2349-57.
2002: Bellantuono Ilaria; Gao Liquan; Parry Suzanne; Marley Steve; Dazzi Francesco; Apperley Jane; Goldman John M; Stauss Hans J
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.
Blood 2002;100(10):3835-7.
2002: Barthe Christophe; Gharbi Marie-Josée; Lagarde Valérie; Chollet Claudine; Cony-Makhoul Pascale; Reiffers Josy; Goldman John M; Melo Junia V; Mahon François Xavier
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
British journal of haematology 2002;119(1):109-11.
2002: Marin David; Marktel Sarah; Bua Marco; Armstrong Lorraine; Goldman John M; Apperley Jane F; Olavarria Eduardo
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
Haematologica 2002;87(9):979-88.
2002: Olavarria Eduardo; Reiffers Josy; Boque Concha; Sureda Ana; Meloni Giovanna; Michallet Mauricette; Clark Richard E; Blaise Didier; Carella Angelo M; Cahn Jean-Yves; Jouet Jean P; Rizzoli Vittorio; Van Biezen Anja; Gratwohl Alois; Goldman John M; Niederwieser Dietger; Apperley Jane F
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.
British journal of haematology 2002;118(3):762-70.
2002: Apperley Jane F; Gardembas Martine; Melo Junia V; Russell-Jones Robin; Bain Barbara J; Baxter E Joanna; Chase Andrew; Chessells Judith M; Colombat Marie; Dearden Claire E; Dimitrijevic Sasa; Mahon François-X; Marin David; Nikolova Zariana; Olavarria Eduardo; Silberman Sandra; Schultheis Beate; Cross Nicholas C P; Goldman John M
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
The New England journal of medicine 2002;347(7):481-7.
2002: Olavarria Eduardo; Craddock Charles; Dazzi Francesco; Marin David; Marktel Sarah; Apperley Jane F; Goldman John M
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Blood 2002;99(10):3861-2.
2002: Wadhwa Jyoti; Szydlo Richard M; Apperley Jane F; Chase Andrew; Bua Marco; Marin David; Olavarria Eduardo; Kanfer Edward; Goldman John M
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.
Blood 2002;99(7):2304-9.
2002: Schultheis Beate; Carapeti-Marootian Melina; Hochhaus Andreas; Weisser Andreas; Goldman John M; Melo Junia V
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.
Blood 2002;99(5):1766-75.
2002: Marley Stephen B; Davidson R John; Goldman John M; Gordon Myrtle Y
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia.
British journal of haematology 2002;116(1):162-5.
2002: Kaeda Jaspal; Chase Andrew; Goldman John M
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia.
Acta haematologica 2002;107(2):64-75.
2001: Vieira S A; Deininger M W; Sorour A; Sinclair P; Foroni L; Goldman J M; Melo J V
Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene.
Genes, chromosomes & cancer 2001;32(4):353-63.
2001: Tipping A J; Mahon F X; Lagarde V; Goldman J M; Melo J V
Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells.
Blood 2001;98(13):3864-7.
2001: Demiroglu A; Steer E J; Heath C; Taylor K; Bentley M; Allen S L; Koduru P; Brody J P; Hawson G; Rodwell R; Doody M L; Carnicero F; Reiter A; Goldman J M; Melo J V; Cross N C
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
Blood 2001;98(13):3778-83.
2001: Mughal T I; Yong A; Szydlo R M; Dazzi F; Olavarria E; van Rhee F; Kaeda J; Cross N C; Craddock C; Kanfer E; Apperley J; Goldman J M
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse.
British journal of haematology 2001;115(3):569-74.
2001: Deininger M W; Vieira S A; Parada Y; Banerji L; Lam E W; Peters G; Mahon F X; Köhler T; Goldman J M; Melo J V
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Cancer research 2001;61(21):8005-13.
2001: Marley S B; Davidson R J; Lewis J L; Nguyen D X; Eades A; Parker S; Goldman J M; Gordon M Y
Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo.
Leukemia research 2001;25(11):997-1002.
2001: Goldman J M; Druker B J
Chronic myeloid leukemia: current treatment options.
Blood 2001;98(7):2039-42.
2001: Sohal J; Chase A; Mould S; Corcoran M; Oscier D; Iqbal S; Parker S; Welborn J; Harris R I; Martinelli G; Montefusco V; Sinclair P; Wilkins B S; van den Berg H; Vanstraelen D; Goldman J M; Cross N C
Identification of four new translocations involving FGFR1 in myeloid disorders.
Genes, chromosomes & cancer 2001;32(2):155-63.
2001: Cwynarski K; Goulding R; Pocock C; Dazzi F; Craddock C; Kaeda J; Olavarria E; Kanfer E; Apperley J; Lawler M; Goldman J M
Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions.
Bone marrow transplantation 2001;28(6):581-6.
2001: Melo J V; Kumberova A; van Dijk A G; Goldman J M; Yuille M R
Investigation on the role of the ATM gene in chronic myeloid leukaemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(9):1448-50.
2001: Dazzi F; Simpson E; Goldman J M
Minor antigen solves major problem.
Nature medicine 2001;7(7):769-70.
2001: Pocock C F; Lucas G F; Giles C; Vassiliou G; Cwynarski K; Rezvani K; Apperley J F; Goldman J M
Immune neutropenia associated with anti-human neutrophil antigen-2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony-stimulating factor.
British journal of haematology 2001;113(2):483-5.
2001: Lewis J L; Chinswangwatanakul W; Zheng B; Marley S B; Nguyen D X; Cross N C; Banerji L; Glassford J; Thomas N S; Goldman J M; Lam E W; Gordon M Y
The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells.
Blood 2001;97(9):2604-10.
2001: Mughal T I; Goldman J M
Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma.
European journal of cancer (Oxford, England : 1990) 2001;37(5):561-8.
2001: Olavarria E; Kanfer E; Szydlo R; Kaeda J; Rezvani K; Cwynarski K; Pocock C; Dazzi F; Craddock C; Apperley J F; Cross N C; Goldman J M
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.
Blood 2001;97(6):1560-5.
2001: Marley S B; Lewis J L; Zheng B; Davidson R J; Davis J G; McDonald C; Alenzi F Q; Goldman J M; Gordon M Y
Peripheral blood progenitor cell mobilisation alters myeloid, but not erythroid, progenitor cell self-renewal kinetics.
Bone marrow transplantation 2001;27(3):241-8.
2001: Craddock C; Szydlo R M; Dazzi F; Olavarria E; Cwynarski K; Yong A; Brookes P; de la Fuente J; Kanfer E; Apperley J F; Goldman J M
Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis.
British journal of haematology 2001;112(1):228-36.
2000: Dazzi F; Szydlo R M; Cross N C; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; Yong A; Apperley J F; Goldman J M
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Blood 2000;96(8):2712-6.
2000: Marley S B; Davidson R J; Goldman J M; Gordon M Y
Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(8):1396-400.
2000: Mahon F X; Deininger M W; Schultheis B; Chabrol J; Reiffers J; Goldman J M; Melo J V
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Blood 2000;96(3):1070-9.
2000: Kulkarni S; Heath C; Parker S; Chase A; Iqbal S; Pocock C F; Kaeda J; Cwynarski K; Goldman J M; Cross N C
Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
Cancer research 2000;60(13):3592-8.
2000: Craddock C; Szydlo R M; Klein J P; Dazzi F; Olavarria E; van Rhee F; Pocock C; Cwynarski K; Apperley J F; Goldman J M
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission.
Blood 2000;96(1):86-90.
2000: Olavarria E; Parker S; Craddock C; Philpott N; Tiniakou M; Chase A; Kanfer E; Apperley J F; Goldman J M
Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization.
Haematologica 2000;85(6):647-52.
2000: Iqbal S; Grimwade D; Chase A; Goldstone A; Burnett A; Goldman J M; Swirsky D
Identification of PML/RARalpha rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients. MRC Adult Leukaemia Working Party.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(5):950-3.
2000: Deininger M W; Vieira S; Mendiola R; Schultheis B; Goldman J M; Melo J V
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Cancer research 2000;60(7):2049-55.
2000: Gao L; Bellantuono I; Elsässer A; Marley S B; Gordon M Y; Goldman J M; Stauss H J
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.
Blood 2000;95(7):2198-203.
2000: Goldman J M
Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia.
Lancet 2000;355(9209):1031-2.
2000: Chase A; Pickard J; Szydlo R; Coulthard S; Goldman J M; Cross N C
Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia.
Genes, chromosomes & cancer 2000;27(3):278-84.
2000: Konstantinidou P; Szydlo R M; Chase A; Goldman J M
Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia.
Bone marrow transplantation 2000;25(2):143-6.
2000: Dazzi F; Szydlo R M; Craddock C; Cross N C; Kaeda J; Chase A; Olavarria E; van Rhee F; Kanfer E; Apperley J F; Goldman J M
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.
Blood 2000;95(1):67-71.
2000: Dazzi F; Hasserjian R; Gordon M Y; Boecklin F; Cotter F; Corbo M; Capelli D; Goldman J M
Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation.
The hematology journal : the official journal of the European Haematology Association / EHA 2000;1(5):307-15.
2000: Gordon M Y; Marley S B; Davidson R J; Grand F H; Lewis J L; Nguyen D X; Lloyd S; Goldman J M
Contact-mediated inhibition of human haematopoietic progenitor cell proliferation may be conferred by stem cell antigen, CD34.
The hematology journal : the official journal of the European Haematology Association / EHA 2000;1(2):77-86.
2000: Sohal J; Reiter A; Goldman J M; Cross N C
Cloning of ZNF237, a novel member of the MYM gene family that maps to human chromosome 13q11-->q12.
Cytogenetics and cell genetics 2000;89(1-2):24-8.
1999: Garrett E; Garin M I; Miller A R; Goldman J M; Melo J V; Apperley J F
Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH-296.
British journal of haematology 1999;107(2):401-8.
1999: Dazzi F; Szydlo R M; Goldman J M
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
Experimental hematology 1999;27(10):1477-86.
1999: Grand F; Kulkarni S; Chase A; Goldman J M; Gordon M; Cross N C
Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia.
Cancer research 1999;59(16):3870-4.
1999: Carapeti M; Aguiar R C; Watmore A E; Goldman J M; Cross N C
Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13).
Cancer genetics and cytogenetics 1999;113(1):70-2.
1999: Marley S B; Lewis J L; Davidson R J; Roberts I A; Dokal I; Goldman J M; Gordon M Y
Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children.
British journal of haematology 1999;106(1):162-6.
1999: MacDonald D H; Lahiri D; Chase A; Sohal J; Goldman J M; Cross N C
A case of myelofibrosis with a t(4;13)(q25;q12): evidence for involvement of a second 13q12 locus in chronic myeloproliferative disorders.
British journal of haematology 1999;105(3):771-4.
1999: Gordon M Y; Dazzi F; Marley S B; Lewis J L; Nguyen D; Grand F H; Davidson R J; Goldman J M
Cell biology of CML cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13 Suppl 1():S65-71.
1999: Stocchi R; Szydlo R; Craddock C; Kanfer E; Apperley J F; Goldman J M; Ward K N
A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation.
Bone marrow transplantation 1999;23(7):705-9.
1999: Chase A; Reiter A; Burci L; Cazzaniga G; Biondi A; Pickard J; Roberts I A; Goldman J M; Cross N C
Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12).
Blood 1999;93(3):1025-31.
1999: Shlebak A A; Marley S B; Roberts I A; Davidson R J; Goldman J M; Gordon M Y
Optimal timing for processing and cryopreservation of umbilical cord haematopoietic stem cells for clinical transplantation.
Bone marrow transplantation 1999;23(2):131-6.
1999: Spencer A; Szydlo R; Grand F H; Goldman J M; Melo J V
Abnormal patterns of immunoglobulin heavy chain gene DNA fingerprinting during chronic phase chronic myeloid leukemia.
Leukemia & lymphoma 1999;32(3-4):299-307.
1999: Kulkarni S; Reiter A; Smedley D; Goldman J M; Cross N C
The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome.
Genomics 1999;55(1):118-21.
1999: Sohal J; Chase A; Goldman J M; Cross N C
Assignment of ZNF262 to human chromosome band 1p34-->p32 by in situ hybridization.
Cytogenetics and cell genetics 1999;85(3-4):306-7.
1998: Shlebak A A; Roberts I A; Stevens T A; Syzdlo R M; Goldman J M; Gordon M Y
The impact of antenatal and perinatal variables on cord blood haemopoietic stem/progenitor cell yield available for transplantation.
British journal of haematology 1998;103(4):1167-71.
1998: Gora-Tybor J; Deininger M W; Goldman J M; Melo J V
The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL.
British journal of haematology 1998;103(3):716-20.
1998: Bose S; Deininger M; Gora-Tybor J; Goldman J M; Melo J V
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
Blood 1998;92(9):3362-7.
1998: Apperley J F; Dazzi F; Craddock C; Goldman J M
Immunotherapy for chronic myeloid leukaemia.
Hematology and cell therapy 1998;40(5):229-32.
1998: Grand F H; Chase A; Iqbal S; Nguyen D X; Lewis J L; Marley S B; Davidson R J; Goldman J M; Gordon M Y
A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
Genes, chromosomes & cancer 1998;23(2):109-15.
1998: Carapeti M; Aguiar R C; Chase A; Goldman J M; Cross N C
Assignment of the steroid receptor coactivator-1 (SRC-1) gene to human chromosome band 2p23.
Genomics 1998;52(2):242-4.
1998: Reiter A; Marley S B; Hochhaus A; Sohal J; Raanani P; Hehlmann R; Gordon M Y; Goldman J M; Cross N C
BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha.
British journal of haematology 1998;102(5):1271-8.
1998: Carapeti M; Aguiar R C; Sill H; Goldman J M; Cross N C
Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells.
British journal of cancer 1998;78(5):601-5.
1998: Reiter A; Sohal J; Kulkarni S; Chase A; Macdonald D H; Aguiar R C; Gonçalves C; Hernandez J M; Jennings B A; Goldman J M; Cross N C
Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome.
Blood 1998;92(5):1735-42.
1998: Gordon M Y; Marley S B; Lewis J L; Davidson R J; Nguyen D X; Grand F H; Amos T A; Goldman J M
Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.
The Journal of clinical investigation 1998;102(4):710-5.
1998: Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Poletti A; Chinswangwatanakul W; Goldman J M; Gordon M Y
The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
Blood 1998;92(4):1390-6.
1998: Deininger M W; Goldman J M
Chronic myeloid leukemia.
Current opinion in hematology 1998;5(4):302-8.
1998: van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; Cross N C; Apperley J; Szydlo R; Goldman J M
Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
Bone marrow transplantation 1998;21(10):1055-61.
1998: Carapeti M; Aguiar R C; Goldman J M; Cross N C
A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.
Blood 1998;91(9):3127-33.
1998: Marley S B; Lewis J L; Goldman J M; Gordon M Y
Discordant erythropoiesis in CML.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(3):444-5.
1998: Coulthard S; Chase A; Orchard K; Watmore A; Vora A; Goldman J M; Swirsky D M
Two cases of inv(8)(p11q13) in AML with erythrophagocytosis: a new cytogenetic variant.
British journal of haematology 1998;100(3):561-3.
1998: O'Donnell J; Goldman J M; Wagner K; Ehinger G; Martin N; Leahy M; Kariuki N; Dokal I; Roberts I
Donor-derived Plasmodium vivax infection following volunteer unrelated bone marrow transplantation.
Bone marrow transplantation 1998;21(3):313-4.
1998: Deininger M W; Bose S; Gora-Tybor J; Yan X H; Goldman J M; Melo J V
Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation.
Cancer research 1998;58(3):421-5.
1998: Lewis J L; Marley S B; Blackett N M; Szydlo R; Goldman J M; Gordon M Y
Interleukin 3 (IL-3), but not stem cell factor (SCF) increases self-renewal by human erythroid burst-forming units (BFU-E) in vitro.
Cytokine 1998;10(1):49-54.
1998: Goldman J M; Schmitz N; Niethammer D; Gratwohl A
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation.
Bone marrow transplantation 1998;21(1):1-7.
1998: Dazzi F; Goldman J M
Adoptive immunotherapy following allogeneic bone marrow transplantation.
Annual review of medicine 1998;49():329-40.
1997: Raanani P; Dazzi F; Sohal J; Szydlo R M; van Rhee F; Reiter A; Lin F; Goldman J M; Cross N C
The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation.
British journal of haematology 1997;99(4):945-50.
1997: Aguiar R C; Chase A; Oscier D G; Carapeti M; Goldman J M; Cross N C
Characterization of a t(10;12)(q24;p13) in a case of CML in transformation.
Genes, chromosomes & cancer 1997;20(4):408-11.
1997: Deininger M W; Goldman J M; Lydon N; Melo J V
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
Blood 1997;90(9):3691-8.
1997: Aguiar R C; Chase A; Coulthard S; Macdonald D H; Carapeti M; Reiter A; Sohal J; Lennard A; Goldman J M; Cross N C
Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement.
Blood 1997;90(8):3130-5.
1997: van Rhee F; Szydlo R M; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb H J; Niederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman J M; Apperley J; Gratwohl A
Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Bone marrow transplantation 1997;20(7):553-60.
1997: Hawkins T E; Marley S B; O'Brien S G; Gordon M Y; Goldman J M
CD34+ cell selection in chronic phase chronic myeloid leukaemia: a comparison of laboratory grade columns.
Bone marrow transplantation 1997;20(5):409-13.
1997: Goldman J M
Chronic myeloid leukemia.
Current opinion in hematology 1997;4(4):277-85.
1997: Carapeti M; Soede-Bobok A; Hochhaus A; Sill H; Touw I P; Goldman J M; Cross N C
Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(7):1005-8.
1997: Hochhaus A; Yan X H; Willer A; Hehlmann R; Gordon M Y; Goldman J M; Melo J V
Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(7):933-9.
1997: Carapeti M; Goldman J M; Cross N C
Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia.
European journal of haematology 1997;58(5):346-9.
1997: Gordon M Y; Lewis J L; Marley S B; Grand F H; Goldman J M
Stromal cells negatively regulate primitive haemopoietic progenitor cell activation via a phosphatidylinositol-anchored cell adhesion/signalling mechanism.
British journal of haematology 1997;96(3):647-53.
1997: Aguiar R C; Sill H; Goldman J M; Cross N C
The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(2):233-8.
1996: Aguiar R C; Sohal J; van Rhee F; Carapeti M; Franklin I M; Goldstone A H; Goldman J M; Cross N C
TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party.
British journal of haematology 1996;95(4):673-7.
1996: Lin F; Kirkland M A; van Rhee F V; Chase A; Coulthard S; Bungey J; Goldman J M; Cross N C
Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Bone marrow transplantation 1996;18(6):1147-52.
1996: Marley S B; Lewis J L; Scott M A; Goldman J M; Gordon M Y
Evaluation of "discordant maturation' in chronic myeloid leukaemia using cultures of primitive progenitor cells and their production of clonogenic progeny (CFU-GM).
British journal of haematology 1996;95(2):299-305.
1996: Seale J R; Varma S; Swirsky D M; Pandolfi P P; Goldman J M; Cross N C
Quantification of PML-RAR alpha transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon.
British journal of haematology 1996;95(1):95-101.
1996: Gordon M Y; Goldman J M
Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment.
British journal of haematology 1996;95(1):10-20.
1996: Aguiar R C; Sill H; Hochhaus A; Goldman J M; Cross N C
Molecular investigation of secondary chronic myeloid leukemia.
Blood 1996;88(7):2808-9.
1996: Rule S A; Savage D G; O'Brien S G; Orchard K; McDonald C; Davidson J; Matthey F; Reilly J T; Bardhan G; Miller E; Cranfield T; Apperley J F; Goldman J M
Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia.
British journal of haematology 1996;94(4):694-8.
1996: Spencer A; Yan X H; Chase A; Goldman J M; Melo J V
BCR-ABL-positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions.
British journal of haematology 1996;94(4):654-8.
1996: Hochhaus A; Reiter A; Skladny H; Melo J V; Sick C; Berger U; Guo J Q; Arlinghaus R B; Hehlmann R; Goldman J M; Cross N C
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
Blood 1996;88(6):2236-40.
1996: Carapeti M; Goldman J M; Cross N C
Overexpression of EVI-1 in blast crisis of chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(9):1561.
1996: Jäger H R; Williams E J; Savage D G; Rule S A; Hajnal J V; Sikora K; Goldman J M; Bydder G M
Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia.
AJNR. American journal of neuroradiology 1996;17(7):1275-82.
1996: Gordon M Y; Lewis J L; Grand F H; Marley S B; Goldman J M
Phenotype and progeny of primitive adherent human hematopoietic progenitors.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(8):1347-53.
1996: Aguiar R C; Dahia P L; Sill H; Toledo S P; Goldman J M; Cross N C
Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas.
Clinical endocrinology 1996;45(1):93-6.
1996: Sill H; Goldman J M; Cross N C
Rarity of microsatellite alterations in acute myeloid leukaemia.
British journal of cancer 1996;74(2):255-7.
1996: Melo J V; Yan X H; Diamond J; Lin F; Cross N C; Goldman J M
Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(7):1217-21.
1996: Al-Jehani F; Hochhaus A; Spencer A; Goldman J M; Melo J V
Expression of the LH2 gene in chronic myeloid leukaemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(7):1122-6.
1996: Marley S B; Lewis J L; Goldman J M; Gordon M Y
Abnormal kinetics of colony formation by erythroid burst-forming units (BFU-E) in chronic myeloid leukaemia.
British journal of haematology 1996;93(4):878-83.
1996: van Rhee F; Hochhaus A; Lin F; Melo J V; Goldman J M; Cross N C
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Blood 1996;87(12):5213-7.
1996: Goldman J M
Autografting for CML--overview and perspectives.
Bone marrow transplantation 1996;17 Suppl 3():S71-4.
1996: Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman J M; Cross N C
Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.
Bone marrow transplantation 1996;17 Suppl 3():S41-4.
1996: Lutz E; Ward K N; Szydlo R; Goldman J M
Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status.
Journal of medical virology 1996;49(1):61-5.
1996: Lin F; van Rhee F; Goldman J M; Cross N C
Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.
Blood 1996;87(10):4473-8.
1996: Sill H; Rule S A; Joske D J; Chase A; Lin F; Goldman J M; Cross N C
Reconstitution with Philadelphia chromosome-negative recipient haematopoiesis early after allogeneic BMT for CML.
Bone marrow transplantation 1996;17(3):453-5.
1996: Zhang J G; Lin F; Chase A; Goldman J M; Cross N C
Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Blood 1996;87(6):2588-93.
1996: Melo J V; Hochhaus A; Yan X H; Goldman J M
Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.
British journal of haematology 1996;92(3):684-6.
1996: Sill H; Aguiar R C; Schmidt H; Hochhaus A; Goldman J M; Cross N C
Mutational analysis of the p15 and p16 genes in acute leukaemias.
British journal of haematology 1996;92(3):681-3.
1996: Clemons M J; Williams Y F; Goldman J M; Barrett A J
Long-term control of polycythemia rubra vera with recombinant alpha interferon.
Hematological oncology 1996;14(1):37-40.
1996: Hochhaus A; Lin F; Reiter A; Skladny H; Mason P J; van Rhee F; Shepherd P C; Allan N C; Hehlmann R; Goldman J M; Cross N C
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
Blood 1996;87(4):1549-55.
1996: Mughal T I; Goldman J M
An integrated approach to the management of chronic myeloid leukemia.
Annals of Saudi medicine 1996;16(1):1-2.
1995: Spencer A; Vulliamy T; Chase A; Goldman J M
Myeloid to lymphoid clonal succession following autologous transplantation in second chronic phase of chronic myeloid leukaemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(12):2138-9.
1995: Spencer A; Szydlo R M; Brookes P A; Kaminski E; Rule S; van Rhee F; Ward K N; Hale G; Waldmann H; Hows J M; Batchelor J R; Goldman J M
Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
Blood 1995;86(9):3590-7.
1995: Amos T A; Lewis J L; Grand F H; Gooding R P; Goldman J M; Gordon M Y
Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids.
British journal of haematology 1995;91(2):387-93.
1995: Macdonald D; Aguiar R C; Mason P J; Goldman J M; Cross N C
A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(10):1628-30.
1995: Spencer A; O'Brien S G; Goldman J M
Options for therapy in chronic myeloid leukaemia.
British journal of haematology 1995;91(1):2-7.
1995: Hochhaus A; Lin F; Reiter A; Skladny H; van Rhee F; Shepherd P C; Allan N C; Hehlmann R; Goldman J M; Cross N C
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
British journal of haematology 1995;91(1):126-31.
1995: Gordon M Y; Lewis J L; Scott M A; Roberts I A; Goldman J M
Probability of progenitor renewal (PPR) and production of clonogenic progeny (CFU-GM) by primitive adherent progenitor cells in adult human bone marrow and umbilical cord blood.
British journal of haematology 1995;90(4):744-9.
1995: Melo J V; Goldman J M
Reply to Haas: Are ABL and BCR imprinted? (Leukemia 1995; 9: 740-743).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(8):1407-8.
1995: Gordon M Y; Blackett N M; Lewis J L; Goldman J M
Evidence for a mechanism that can provide both short-term and long-term haemopoietic repopulation by a seemingly uniform population of primitive human haemopoietic precursor cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(7):1252-6.
1995: Lin F; Chase A; Bungey J; Goldman J M; Cross N C
Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia.
Genes, chromosomes & cancer 1995;13(2):110-4.
1995: Lanza F; Bi S; Moretti S; Castoldi G; Goldman J M
Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.
British journal of haematology 1995;90(1):8-14.
1995: van Rhee F; Kasprzyk A; Jamil A; Dickinson H; Lin F; Cross N C; Galvin M C; Goldman J M; Secker-Walker L M
Detection of the BCR-ABL gene by reverse transcription/polymerase chain reaction and fluorescence in situ hybridization in a patient with Philadelphia chromosome negative acute lymphoblastic leukaemia.
British journal of haematology 1995;90(1):225-8.
1995: Zhang J G; Goldman J M; Cross N C
Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR.
British journal of haematology 1995;90(1):138-46.
1995: Spencer A; Brookes P A; Kaminski E; Hows J M; Szydlo R M; van Rhee F; Goldman J M; Batchelor J R
Cytotoxic T lymphocyte precursor frequency analyses in bone marrow transplantation with volunteer unrelated donors. Value in donor selection.
Transplantation 1995;59(9):1302-8.
1995: Melo J V; Yan X H; Diamond J; Goldman J M
Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(4):734-9.
1995: Diamond J; Goldman J M; Melo J V
BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
Blood 1995;85(8):2171-5.
1995: Sill H; Goldman J M; Cross N C
Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.
Blood 1995;85(8):2013-6.
1995: van Rhee F; Marks D I; Lin F; Szydlo R M; Hochhaus A; Treleaven J; Delord C; Cross N C; Goldman J M
Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(2):329-35.
1994: Schwarer A P; Jiang Y Z; Deacock S; Brookes P A; Barrett A J; Goldman J M; Batchelor J R; Lechler R I
Comparison of helper and cytotoxic antirecipient T cell frequencies in unrelated bone marrow transplantation.
Transplantation 1994;58(11):1198-203.
1994: Melo J V; Kent N S; Yan X H; Goldman J M
Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts.
Blood 1994;84(11):3984-6.
1994: Melo J V; Yan X H; Diamond J; Goldman J M
Lack of imprinting of the ABL gene.
Nature genetics 1994;8(4):318-9.
1994: O'Brien S G; Kirkland M A; Melo J V; Rao M H; Davidson R J; McDonald C; Goldman J M
Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(12):2156-62.
1994: Silly H; Chase A; Mills K I; Apfelbeck U; Sormann S; Goldman J M; Cross N C
No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(11):1923-8.
1994: van Rhee F; Lin F; Cross N C; Reid C D; Lakhani A K; Szydlo R M; Goldman J M
Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia.
Bone marrow transplantation 1994;14(4):609-12.
1994: Garicochea B; van Rhee F; Spencer A; Chase A; Lin F; Cross N C; Goldman J M
Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH).
British journal of haematology 1994;88(2):400-2.
1994: Hoyle C; Goldman J M
Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams.
Bone marrow transplantation 1994;14(2):247-52.
1994: Garicochea B; Chase A; Lazaridou A; Goldman J M
T lymphocytes in chronic myelogenous leukaemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(7):1197-201.
1994: Kirkland M A; O'Brien S G; Goldman J M
Antisense therapeutics in haematological malignancies.
British journal of haematology 1994;87(3):447-52.
1994: Savage D G; Goldman J M
Approaches to the treatment of chronic myeloid leukemia.
International journal of hematology 1994;60(1):1-21.
1994: van Rhee F; Lin F; Cullis J O; Spencer A; Cross N C; Chase A; Garicochea B; Bungey J; Barrett J; Goldman J M
Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.
Blood 1994;83(11):3377-83.
1994: Macdonald D; Sheerin S M; Cross N C; Spencer A; Goldman J M
An atypical myeloproliferative disorder with t(8;13) (p11;q12): a third case.
British journal of haematology 1994;86(4):879-80.
1994: Goldman J M
Management of chronic myeloid leukaemia.
Blood reviews 1994;8(1):21-9.
1994: Lin F; Goldman J M; Cross N C
A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia.
British journal of haematology 1994;86(3):683-5.
1994: Ramrakha P S; Marks D I; O'Brien S G; Yacoub M; Schofield J B; Goldman J M
Orthotopic cardiac transplantation for dilated cardiomyopathy after allogeneic bone marrow transplantation.
Clinical transplantation 1994;8(1):23-6.
1994: Melo J V; Myint H; Galton D A; Goldman J M
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(1):208-11.
1994: Cross N C; Melo J V; Feng L; Goldman J M
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(1):186-9.
1994: Cullis J O; Barrett A J; Goldman J M; Lechler R I
Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(1):165-70.
1994: Bi S; Barton C M; Lemoine N R; Cross N C; Goldman J M
Retroviral transduction of Philadelphia-positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation.
Experimental hematology 1994;22(1):95-9.
1994: Bi S; Lanza F; Goldman J M
The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis.
Cancer research 1994;54(2):582-6.
1994: Goldman J M
Autografting for CML--where does it fit in to the overall treatment strategy?
Bone marrow transplantation 1994;14 Suppl 3():S74-7.
1994: O'Brien S G; Kirkland M A; Goldman J M
European School of Oncology Task Force Papers: gene therapy--a future in cancer management? Antisense therapy for malignant disease.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1160-4.
1993: Bi S; Lanza F; Goldman J M
The abnormal p53 proteins expressed in CML cell lines are non-functional.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(11):1840-5.
1993: Mughal T; Hoyle C; Goldman J M
Autografting for patients with chronic myeloid leukemia--the Hammersmith experience.
Stem cells (Dayton, Ohio) 1993;11 Suppl 3():20-2.
1993: Barrett J; Guimaraes A; Cullis J; Goldman J M
Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
Stem cells (Dayton, Ohio) 1993;11 Suppl 3():104-8.
1993: Lanza F; Bi S; Castoldi G; Goldman J M
Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(10):1570-5.
1993: Cross N C; Feng L; Chase A; Bungey J; Hughes T P; Goldman J M
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Blood 1993;82(6):1929-36.
1993: Kirkland M A; O'Brien S G; McDonald C; Davidson R J; Cross N C; Goldman J M
BCR-ABL antisense purging in chronic myeloid leukaemia.
Lancet 1993;342(8871):614.
1993: De Fabritiis P; Dowding C; Bungey J; Chase A; Angus G; Szydlo R; Goldman J M
Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells.
Leukemia & lymphoma 1993;11(1-2):51-61.
1993: Marks D I; Cullis J O; Ward K N; Lacey S; Syzdlo R; Hughes T P; Schwarer A P; Lutz E; Barrett A J; Hows J M; Batchelor J R; Goldman J M
Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years.
Annals of internal medicine 1993;119(3):207-14.
1993: Melo J V; Gordon D E; Tuszynski A; Dhut S; Young B D; Goldman J M
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Blood 1993;81(10):2488-91.
1993: Hoyle C; Goldman J M
Pyomyositis in a patient with myeloma responding to antibiotics alone.
Journal of internal medicine 1993;233(5):419-21.
1993: Nathwani A C; Goldman J M
Management of chronic myeloid leukaemia in lymphoid blast transformation.
Haematologica 1993;78(3):162-6.
1993: Cross N C; Hughes T P; Feng L; O'Shea P; Bungey J; Marks D I; Ferrant A; Martiat P; Goldman J M
Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse.
British journal of haematology 1993;84(1):67-74.
1993: Batchelor J R; Schwarer A P; Yin Z J; Barrett A J; Goldman J M; Lechler R I
Helper T-lymphocyte precursor frequencies predict risks of graft-versus-host disease in bone marrow transplantation.
Transplantation proceedings 1993;25(1 Pt 2):1237-8.
1993: Jiang Y Z; Cullis J O; Kanfer E J; Goldman J M; Barrett A J
T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia.
Bone marrow transplantation 1993;11(2):133-8.
1993: Melo J V; Gordon D E; Cross N C; Goldman J M
The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.
Blood 1993;81(1):158-65.
1993: Schwarer A P; Jiang Y Z; Brookes P A; Barrett A J; Batchelor J R; Goldman J M; Lechler R I
Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation.
Lancet 1993;341(8839):203-5.
1993: Goldman J M
Chronic myeloid leukaemia--the XXI century.
Leukemia & lymphoma 1993;11 Suppl 1():7-9.
1993: Cross N C; Feng L; Bungey J; Goldman J M
Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction.
Leukemia & lymphoma 1993;11 Suppl 1():39-43.
1992: Schwarer A P; Hughes J M; Trotman-Dickenson B; Krausz T; Goldman J M
A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation.
Transplantation 1992;54(6):1002-8.
1992: Marks D I; Dousset B; Robson A; Imvrios G; Buckels J A; Elias E; Neuberger J M; Foster C; Batchelor R; Goldman J M
Orthotopic liver transplantation for hepatic GVHD following allogeneic BMT for chronic myeloid leukaemia.
Bone marrow transplantation 1992;10(5):463-6.
1992: Bi S; Hughes T; Bungey J; Chase A; de Fabritiis P; Goldman J M
p53 in chronic myeloid leukemia cell lines.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(8):839-42.
1992: Melo J V; Goldman J M
Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(8):786-90.
1992: Cullis J O; Marks D I; Schwarer A P; Barrett A J; Hows J M; Swirsky D M; Goldman J M
Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukaemia: a report of five cases.
British journal of haematology 1992;81(3):378-82.
1992: Kaminski E R; Hows J M; Goldman J M; Batchelor J R
Lymphocytes from multi-transfused patients exhibit cytotoxicity against autologous cells.
British journal of haematology 1992;81(1):23-6.
1992: Deacock S J; Schwarer A P; Bridge J; Batchelor J R; Goldman J M; Lechler R I
Evidence that umbilical cord blood contains a higher frequency of HLA class II-specific alloreactive T cells than adult peripheral blood. A limiting dilution analysis.
Transplantation 1992;53(5):1128-34.
1992: Goldman J M
Bone marrow transplantation for chronic myelogenous leukemia.
Current opinion in oncology 1992;4(2):259-63.
1992: Cullis J O; Jiang Y Z; Schwarer A P; Hughes T P; Barrett A J; Goldman J M
Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation.
Blood 1992;79(5):1379-81.
1992: Cullis J O; Schwarer A P; Hughes T P; Hows J M; Franklin I; Morgenstern G; Goldman J M
Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning.
British journal of haematology 1992;80(1):33-9.
1992: Goldman J M
Bone marrow transplantation for chronic myeloid leukaemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():22-3.
1991: Jiang Y Z; Kanfer E J; Macdonald D; Cullis J O; Goldman J M; Barrett A J
Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells.
Bone marrow transplantation 1991;8(4):253-8.
1991: Weide R; Dowding C; Sucai B; Bungey J; Chase A; Goldman J M
Inactivation of the retinoblastoma susceptibility gene in a human high grade non-Hodgkin's lymphoma cell line.
British journal of haematology 1991;78(4):500-5.
1991: Gordon M Y; Atkinson J; Clarke D; Dowding C R; Goldman J M; Grimsley P G; Siczkowski M; Greaves M F
Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(8):693-8.
1991: Kaminski E R; Hows J M; Bridge J; Davey N J; Brookes P A; Green J E; Goldman J M; Batchelor J R
Cytotoxic T lymphocyte precursor (CTL-p) frequency analysis in unrelated donor bone marrow transplantation: two case studies.
Bone marrow transplantation 1991;8(1):47-50.
1991: Bashey A; Vulliamy T; Cai B S; Schwarer A P; Goldman J M
Non-lymphoid blast crisis of CML with rearrangement of immunoglobulin and T-cell receptor delta genes.
European journal of haematology 1991;47(1):36-41.
1991: Osterholz J; Dowding C; Guo A P; Siczkowski M; Goldman J M
Interferon-alpha alters the distribution of CFU-GM between the adherent and nonadherent compartments in long-term cultures of chronic myeloid leukemia marrow.
Experimental hematology 1991;19(5):326-31.
1991: Dowding C; Guo A P; Maisin D; Gordon M Y; Goldman J M
The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint.
British journal of haematology 1991;77(2):165-71.
1991: Hughes T P; Morgan G J; Martiat P; Goldman J M
Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse.
Blood 1991;77(4):874-8.
1991: Mackinnon S; Bungey J; Chase A; Paulsen W; Hows J M; Goldman J M
Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation.
British journal of haematology 1991;77(1):60-5.
1991: Goldman J M; Hughes T
Detection and significance of minimal residual disease in patients with leukaemia and lymphoma.
Bone marrow transplantation 1991;7 Suppl 1():66-9.
1991: Goldman J M
Bone marrow transplantation for chronic myeloid leukaemia.
Bone marrow transplantation 1991;7 Suppl 2():62-3.
1991: Hughes T P; O'Shea P; Morgan G; Martiat P; Goldman J M
Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse.
Bone marrow transplantation 1991;7 Suppl 2():23.
1990: Kaminski E R; Hows J M; Goldman J M; Batchelor J R
Pretransfused patients with severe aplastic anaemia exhibit high numbers of cytotoxic T lymphocyte precursors probably directed at non-HLA antigens.
British journal of haematology 1990;76(3):401-5.
1990: Mackinnon S; Hows J M; Goldman J M
Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia.
Blood 1990;76(10):2037-45.
1990: Hernandez A; Osterholz J; Price C M; Wiedemann L M; Gordon M Y; Goldman J M; Morgan G J
Detection of the hybrid BCR/ABL messenger RNA in single CFU-GM colonies using the polymerase chain reaction.
Experimental hematology 1990;18(10):1142-4.
1990: Mackinnon S; Hows J M; Goldman J M; Arthur C K; Hughes T; Apperley J F; Jones L; Batchelor J R; Brookes P; Catovsky D
Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors.
Experimental hematology 1990;18(5):421-5.
1990: Batchelor J R; Kaminski E; Lombardi G; Goldman J M; Lechler R I
Individual variation in alloresponsiveness and the molecular basis of allorecognition.
Human immunology 1990;28(2):96-103.
1990: Mackinnon S; Hows J M; Goldman J M
Induction of a syngeneic graft-versus-leukemia effect following bone marrow transplantation for chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(4):287-91.
1990: Goldman J M; Grosveld G; Baltimore D; Gale R P
Chronic myelogenous leukemia--the unfolding saga.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(3):163-7.
1990: Goldman J M
Molecular biology and treatment of chronic myelogenous leukemia.
Current opinion in oncology 1990;2(1):49-54.
1990: Hughes T P; Goldman J M
Biological importance of residual leukaemic cells after BMT for CML: does the polymerase chain reaction help?
Bone marrow transplantation 1990;5(1):3-6.
1990: Jaubert J; Martiat P; Dowding C; Ifrah N; Goldman J M
The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukemia.
British journal of haematology 1990;74(1):30-5.
1989: Goldman J M; Mackinnon S
Bone marrow transplantation for chronic myeloid leukaemia using matched unrelated donors.
Bone marrow transplantation 1989;4 Suppl 4():38-9.
1989: Hughes T P; Economou K; Mackinnon S; Vlitos M; Arthur C K; Guo A P; Rassool F; Apperley J F; Hows J; Goldman J M
Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow.
British journal of haematology 1989;73(4):462-7.
1989: Kaminski E; Hows J; Man S; Brookes P; Mackinnon S; Hughes T; Avakian O; Goldman J M; Batchelor J R
Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation.
Transplantation 1989;48(4):608-13.
1989: Martiat P; Ifrah N; Rassool F; Morgan G; Giles F; Gow J; Goldman J M
Molecular analysis of Philadelphia positive essential thrombocythemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(8):563-5.
1989: Bowcock S J; Galton D A; Goldman J M
Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia.
European journal of haematology 1989;42(5):496-7.
1989: Morgan G J; Hughes T; Janssen J W; Gow J; Guo A P; Goldman J M; Wiedemann L M; Bartram C R
Polymerase chain reaction for detection of residual leukaemia.
Lancet 1989;1(8644):928-9.
1989: James N D; Apperley J F; Kam K C; MacKinnon S; Goldman J M; Goolden A W; Sikora K
Total lymphoid irradiation preceding bone marrow transplantation for chronic myeloid leukaemia.
Clinical radiology 1989;40(2):195-8.
1989: Goldman J M
Allogeneic bone marrow transplantation: state of the art and future directions.
Bone marrow transplantation 1989;4 Suppl 1():133-4.
1989: Dokal I; Jones L; Deenmamode M; Lewis S M; Goldman J M
Allogeneic bone marrow transplantation for primary myelofibrosis.
British journal of haematology 1989;71(1):158-60.
1989: Apperley J F; Dowding C; Hibbin J; Buiter J; Matutes E; Sissons P J; Gordon M; Goldman J M
The effect of cytomegalovirus on hemopoiesis: in vitro evidence for selective infection of marrow stromal cells.
Experimental hematology 1989;17(1):38-45.
1989: Goldman J M
Recent advances in molecular biology of chronic myeloid leukaemia: is the pathogenetic puzzle approaching solution?
Bone marrow transplantation 1989;4 Suppl 1():129-30.
1988: Price C M; Rassool F; Shivji M K; Gow J; Tew C J; Haworth C; Goldman J M; Wiedemann L M
Rearrangement of the breakpoint cluster region and expression of P210 BCR-ABL in a "masked" Philadelphia chromosome-positive acute myeloid leukemia.
Blood 1988;72(5):1829-32.
1988: Weitzel J N; Hows J M; Jeffreys A J; Min G L; Goldman J M
Use of a hypervariable minisatellite DNA probe (33.15) for evaluating engraftment two or more years after bone marrow transplantation for aplastic anaemia.
British journal of haematology 1988;70(1):91-7.
1988: Koeppler H; Goldman J M
'Auto'-immune neutropenia after allogeneic bone marrow transplantation unresponsive to conventional immunosuppression but resolving promptly after splenectomy.
European journal of haematology 1988;41(2):182-5.
1988: Apperley J F; Goldman J M
Cytomegalovirus: biology, clinical features and methods for diagnosis.
Bone marrow transplantation 1988;3(4):253-64.
1988: Apperley J F; Mauro F R; Goldman J M; Gregory W; Arthur C K; Hows J; Arcese W; Papa G; Mandelli F; Wardle D
Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.
British journal of haematology 1988;69(2):239-45.
1988: Arthur C K; Apperley J F; Guo A P; Rassool F; Gao L M; Goldman J M
Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase.
Blood 1988;71(5):1179-86.
1988: Ganly P S; Arthur C; Goldman J M; Schulenburg W E
Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
Postgraduate medical journal 1988;64(751):389-91.
1988: Dowding C R; Gordon M Y; Goldman J M
Increased DR antigen expression by committed hemopoietic progenitor cells but not primitive progenitor cells in chronic myeloid leukemia.
Experimental hematology 1988;16(3):171-5.
1988: Mackinnon S; Goldman J M
Bone marrow transplantation for patients with chronic myeloid leukaemia.
British journal of hospital medicine 1988;39(3):226-30.
1987: Goldman J M
Bone marrow transplantation for chronic myeloid leukaemia.
Hematological oncology 1987;5(4):265-79.
1987: Goldman J M
Prospects for cure in leukaemia.
Journal of clinical pathology 1987;40(9):985-94.
1987: Jones L; Thein S L; Jeffreys A J; Apperley J F; Catovsky D; Goldman J M
Identical twin marrow transplantation for 5 patients with chronic myeloid leukaemia: role of DNA finger-printing to confirm monozygosity in 3 cases.
European journal of haematology 1987;39(2):144-7.
1987: Jones L; Ball J; Apperley J F; Ginsberg L; Goldman J M
Subacute thyroiditis after bone marrow transplant for chronic granulocytic leukaemia.
Bone marrow transplantation 1987;1(4):411-2.
1987: Ganesan T S; Rassool F; Guo A P; Young B D; Galton D A; Goldman J M
Rearrangement of the bcr gene in Philadelphia-chromosome-negative chronic myeloid leukemia.
Haematology and blood transfusion 1987;31():153-9.
1987: Brito-Babapulle F; Apperley J F; Rassool F; Guo A P; Dowding C; Goldman J M
Complete remission after autografting for chronic myeloid leukaemia.
Leukemia research 1987;11(12):1115-7.
1986: Robak T; Dowding C; Garewal G; Hibbin J A; Th'ng K H; Goldman J M
Antigenic determinants on myeloid leukaemia colony-forming cells resemble those of normal myeloid progenitor cells and differ from those of circulating blast cells.
British journal of haematology 1986;64(1):133-48.
1986: Martin H; Hibbin J A; Dowding C; Matutes E; Tindle R; Goldman J M
Purification of haemopoietic progenitor cells from patients with chronic granulocytic leukaemia using percoll density gradients and elutriation.
British journal of haematology 1986;63(1):187-98.
1985: Gordon M Y; Hibbin J A; Dowding C; Gordon-Smith E C; Goldman J M
Separation of human blast progenitors from granulocytic, erythroid, megakaryocytic, and mixed colony-forming cells by "panning" on cultured marrow-derived stromal layers.
Experimental hematology 1985;13(9):937-40.
1984: Haines M E; Goldman J M; Worsley A M; McCarthy D M; Wyatt S E; Dowding C; Kearney L; Th'ng K H; Wareham N J; Pollock A
Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients.
British journal of haematology 1984;58(4):711-21.
1984: Dowding C; Th'ng K H; Goldman J M; Galton D A
Increased T-lymphocyte numbers in chronic granulocytic leukemia before treatment.
Experimental hematology 1984;12(10):811-15.
1984: Baughan A S; Worsley A M; McCarthy D M; Hows J M; Catovsky D; Gordon-Smith E C; Galton D A; Goldman J M
Haematological reconstitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocytic leukaemia: the influence of previous splenectomy.
British journal of haematology 1984;56(3):445-54.
1983: Goolden A W; Goldman J M; Kam K C; Dunn P A; Baughan A S; McCarthy D M; Worsley A M; Gordon-Smith E C; Samson D; Catovsky D; Galton D A
Fractionation of whole body irradiation before bone marrow transplantation for patients with leukaemia.
The British journal of radiology 1983;56(664):245-50.
1983: Mehta A B; Baughan A S; Catovsky D; Goldman J M; Johnson S A; Galton D A
Reversal of marrow fibrosis in acute megakaryoblastic leukaemia after remission-induction and consolidation chemotherapy followed by bone marrow transplantation.
British journal of haematology 1983;53(3):445-9.
1982: Goldman J M; Hibbin J; Kearney L; Orchard K; Th'ng K H
HLA-DR monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukaemia myeloid progenitor cells.
British journal of haematology 1982;52(3):411-20.
1982: Goldman J M; Baughan A S; McCarthy D M; Worsley A M; Hows J M; Gordon-Smith E C; Catovsky D; Batchelor J R; Goolden A W; Galton D A
Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia.
Lancet 1982;2(8299):623-5.
1982: Kearney L; Orchard K H; Hibbin J; Goldman J M
T-cell cytogenetics in chronic granulocytic leukaemia.
Lancet 1982;1(8276):858.
1981: Goldman J M; Catovsky D; Goolden A W; Johnson S A; Galton D A
Buffy coat autografts for patients with chronic granulocytic leukaemia in transformation.
Blut 1981;42(3):149-55.
1981: Goldman J M; Johnson S A; Catovsky D; Agnarsdottir G; Goolden A W; Galton D A
Identical twin marrow transplantation for patients with leukemia and lymphoma.
Transplantation 1981;31(2):140-1.
1980: Goldman J M; Shiota F; Th'ng K H; Orchard K H
Circulating granulocytic and erythroid progenitor cells in chronic granulocytic leukaemia.
British journal of haematology 1980;46(1):7-13.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

John Goldman

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Anatomy

Concepts & Ideas

Physiology

Genes & Molecular Sequences

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of John Goldman (preview)

All Publications